Elizabeth Laws

3.1k total citations · 5 hit papers
65 papers, 950 citations indexed

About

Elizabeth Laws is a scholar working on Physiology, Surgery and Immunology. According to data from OpenAlex, Elizabeth Laws has authored 65 papers receiving a total of 950 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Physiology, 24 papers in Surgery and 23 papers in Immunology. Recurrent topics in Elizabeth Laws's work include Asthma and respiratory diseases (30 papers), Eosinophilic Esophagitis (24 papers) and IL-33, ST2, and ILC Pathways (19 papers). Elizabeth Laws is often cited by papers focused on Asthma and respiratory diseases (30 papers), Eosinophilic Esophagitis (24 papers) and IL-33, ST2, and ILC Pathways (19 papers). Elizabeth Laws collaborates with scholars based in United States, France and Germany. Elizabeth Laws's co-authors include Leda Mannent, Bolanle Akinlade, Jennifer Maloney, Nikhil Amin, Nadia Daizadeh, Naimish Patel, Ashish Bansal, Yamo Deniz, Juby A. Jacob‐Nara and George D. Yancopoulos and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Gastroenterology.

In The Last Decade

Elizabeth Laws

58 papers receiving 941 citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis

2022 146 citations Amr Radwan, Nadia Daizadeh et al. profile →
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

2023 119 citations Elizabeth Laws, Leda Mannent et al. profile →
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

2024 102 citations Surya P. Bhatt, Klaus F. Rabe et al. profile →
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

2024 65 citations Marcus Maurer, Thomas B. Casale et al. Journal of Allergy and Clinical Immunology profile →
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

2025 18 citations Surya P. Bhatt, Klaus F. Rabe et al. The Lancet Respiratory Medicine profile →

Peers

Countries citing papers authored by Elizabeth Laws

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Laws's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Laws with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Laws more than expected).

Fields of papers citing papers by Elizabeth Laws

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Laws. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Laws. The network helps show where Elizabeth Laws may publish in the future.

Co-authorship network of co-authors of Elizabeth Laws

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Laws. A scholar is included among the top collaborators of Elizabeth Laws based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Laws. Elizabeth Laws is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia–Pacific Region 2025 ·Clinical & Experimental Allergy ·(unknown), Nanshan Zhong, Sahajal Dhooria, (unknown), Haohui Fang, Jie Lin, Shuyang Zhu, Elizabeth Laws, Yi Wang, Vivian Li, (unknown), Jennifer Maloney, Raolat M. Abdulai, Lacey B. Robinson	1
2	Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial 2025 ·The Lancet Respiratory Medicine ·Stephanie A. Christenson, Nicola A. Hanania, Surya P. Bhatt, Mona Bafadhel, Klaus F. Rabe, Claus Vogelmeier, Alberto Papi, (unknown), Elizabeth Laws, Paula Dakin, Ashish Bansal, Xin Lu, (unknown), Jennifer Maloney, Lacey B. Robinson, Raolat M. Abdulai	5
3	Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS 2025 ·CHEST Journal ·Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania, Claus Vogelmeier, Mona Bafadhel, (unknown), Alberto Papi, Dave Singh, Elizabeth Laws, Paula Dakin, Jennifer Maloney, Xin Lu, (unknown), Ashish Bansal, Raolat M. Abdulai, Lacey B. Robinson	1
4	Dupilumab Improves Lung Function, Asthma Control and Exacerbation Frequency in Allergic Bronchopulmonary Aspergillosis – Results from the Phase 2 LIBERTY ABPA AIRED Study 2025 ·American Journal of Respiratory and Critical Care Medicine ·Arnaud Bourdin, (unknown), Anand Shah, Caroline Baxter, (unknown), Nikhil Amin, (unknown), (unknown), Andrew P. Fontenot, Paula Dakin, Elizabeth Laws, Jennifer Maloney, (unknown), Allen Radin	2
5	Dupilumab efficacy in patients with asthma and allergic bronchopulmonary aspergillosis (ABPA) 2025 ·Arnaud Bourdin, Jonathan Corren, Anand Shah, Caroline Baxter, (unknown), (unknown), (unknown), Andrew P. Fontenot, Paula Dakin, Elizabeth Laws, Jennifer Maloney, Lacey B. Robinson, Allen Radin	0
6	Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma 2024 ·Journal of Allergy and Clinical Immunology ·Leonard B. Bacharier, Ian Pavord, Jorge Máspero, Daniel J. Jackson, Alessandro Fiocchi, (unknown), Juby A. Jacob‐Nara, Yamo Deniz, Elizabeth Laws, Leda Mannent, Nikhil Amin, Bolanle Akinlade, Heribert Staudinger, David J. Lederer, Megan Hardin	23
7	Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials breakdown → 2024 ·Journal of Allergy and Clinical Immunology ·Marcus Maurer, Thomas B. Casale, Sarbjit S. Saini, Moshe Ben‐Shoshan, Ana M. Giménez‐Arnau, Jonathan A. Bernstein, Akiko Yagami, (unknown), Allen Radin, Heribert Staudinger, Naimish Patel, Nikhil Amin, Bolanle Akinlade, Chunpeng Fan, Déborah Bauer, George D. Yancopoulos, Kiran Patel, Leda Mannent, Elizabeth Laws	65
8	Dupilumab Improves Pre-bronchodilator Lung Function Measures in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 Boreas Trial 2024 ·Alberto Papi, Nicola A. Hanania, Surya P. Bhatt, Klaus F. Rabe, Claus Vogelmeier, Mona Bafadhel, Stephanie A. Christenson, Dave Singh, Elizabeth Laws, (unknown), Ashish Bansal, (unknown), Dirk Bauer, Jennifer Maloney, Lacey B. Robinson, Raolat M. Abdulai	1
9	Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels 2024 ·Dermatology and Therapy ·Marcus Maurer, Thomas B. Casale, Sarbjit S. Saini, (unknown), Elizabeth Laws, Jennifer Maloney, Déborah Bauer, Allen Radin, Melanie Makhija	9
10	In the Phase 3 Boreas Trial, Baseline Blood Eosinophils and Baseline Fractional Exhaled Nitric Oxide Levels Predict the Response to Dupilumab in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease and Type 2 Inflammation 2024 ·Stephanie A. Christenson, Nicola A. Hanania, Surya P. Bhatt, Mona Bafadhel, Klaus F. Rabe, Claus Vogelmeier, Alberto Papi, Dave Singh, Elizabeth Laws, (unknown), Ashish Bansal, Xun‐Xi Lu, Dirk Bauer, Jennifer Maloney, (unknown), Raolat M. Abdulai	1
11	Sa1275 IMPROVEMENTS IN HISTOLOGIC, SYMPTOMATIC, AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS ARE MAINTAINED, OR CONTINUE TO IMPROVE, WITH LONG-TERM DUPILUMAB TREATMENT, REGARDLESS OF PRIOR ESOPHAGEAL DILATION 2024 ·Gastroenterology ·Albert J. Bredenoord, Evan S. Dellon, Ikuo Hirano, Changming Xia, Elizabeth Laws, Michael C. Nivens, Raolat M. Abdulai, Jennifer Maloney, Lila Glotfelty, Arsalan Shabbir	1
12	Dupilumab significantly improves itch and hives in patients with chronic spontaneous urticaria (CUPID study C) 2024 ·Annals of Allergy Asthma & Immunology ·(unknown), Sarbjit S. Saini, Jonine L. Bernstein, Ana M. Giménez‐Arnau, Déborah Bauer, Nikhil Amin, (unknown), Paula Dakin, Elizabeth Laws, Allen Radin, Melanie Makhija	3
13	Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy 2024 ·Allergy ·Matthew F. Wipperman, Kaitlyn Gayvert, Amanda Atanasio, Claire Q. Wang, Jonathan Corren, (unknown), Ian Setliff, (unknown), Elizabeth Laws, (unknown), Sivan Harel, Jennifer Maloney, Gary Herman, Jamie Orengo, Wei Keat Lim, Sara Hamon, Jennifer D. Hamilton, Meagan P. O’Brien	12
14	P726 A phase 2 study investigating the efficacy and safety of dupilumab versus placebo in adults with moderately to severely active ulcerative colitis with an eosinophilic phenotype 2024 ·Journal of Crohn s and Colitis ·Eyal Gottlieb, David G. Binion, Brian G. Feagan, Elizabeth Laws, (unknown), Jennifer Maloney, (unknown), Allen Radin, (unknown)	0
15	605 DUPILUMAB IMPROVES HISTOLOGIC AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS IN CHILDREN AGED 1-11 YEARS IN THE PHASE 3 EOE KIDS TRIAL 2023 ·Gastroenterology ·Mirna Chehade, Evan S. Dellon, Jonathan M. Spergel, Marc E. Rothenberg, Ruiqi Liu, Leda Mannent, Elizabeth Laws, (unknown), Jennifer Maloney, (unknown), Bethany Beazley, Lila Glotfelty, Arsalan Shabbir	1
16	Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results 2023 ·Annals of Otology Rhinology & Laryngology ·Claus Bachert, Tanya M. Laidlaw, Seong Cho, Joaquim Mullol, Brian N. Swanson, Souâd Naimi, Marion Classe, Sivan Harel, Alexandre Jagerschmidt, Elizabeth Laws, Marcella Ruddy, Amy Praestgaard, Nikhil Amin, Leda Mannent	16
17	Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose 2023 ·Allergy ·Ian Pavord, Arnaud Bourdin, Alberto Papi, Christian Domingo, Jonathan Corren, Arman Altincatal, Amr Radwan, (unknown), Juby A. Jacob‐Nara, Yamo Deniz, Paul J. Rowe, Elizabeth Laws, David J. Lederer, Megan Hardin	6
18	Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction 2022 ·Annals of Allergy Asthma & Immunology ·Nicola A. Hanania, Mario Castro, Eric D. Bateman, Ian Pavord, Alberto Papi, J. Mark FitzGerald, Jorge Máspero, Constance H. Katelaris, Dave Singh, Nadia Daizadeh, Arman Altincatal, (unknown), Xavier Soler, Shahid Siddiqui, Elizabeth Laws, Juby A. Jacob‐Nara, Paul J. Rowe, David J. Lederer, Megan Hardin, Yamo Deniz	8
19	LONG-TERM EFFECT OF DUPILUMAB ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 ASTHMA: LIBERTY ASTHMA TRAVERSE STUDY 2021 ·CHEST Journal ·Alberto Papi, Mario Castro, Jonathan Corren, Ian Pavord, Yuji Tohda, Nadia Daizadeh, Benjamin Ortiz, Michel Djandji, Marcella Ruddy, Elizabeth Laws, Leda Mannent, Nikhil Amin, (unknown), Juby A. Jacob‐Nara, Yamo Deniz, Paul Rowe, David J. Lederer, Megan Hardin	1
20	Indomethacin in rheumatoid arthritis. Comparison of oral and rectal administration 1979 ·British Journal of Clinical Pharmacology ·N. Baber, L. Halliday, Elizabeth Laws, (unknown), M. Orme, R. Sibeon	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact